ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Targeted Drugs for Neurodegenerative Diseases Market Research Report 2026
Published Date: 2026-02-11
|
Report Code: QYRE-Auto-1Q18062
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Targeted Drugs for Neurodegenerative Diseases Market Research Report 2024
BUY CHAPTERS

Global Targeted Drugs for Neurodegenerative Diseases Market Research Report 2026

Code: QYRE-Auto-1Q18062
Report
2026-02-11
Pages:133
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
ACADIA Pharmaceuticals Inc.
Kyowa Kirin
Supernus Pharmaceuticals
UCB
Sumitomo Pharma
Biogen
Eisai Co Ltd
Eli Lilly
Green Valley
Novartis
Bristol–Myers Squibb
Janssen
Sanofi
Roche
Neurocrine
Lundbeck
TEVA

Targeted Drugs for Neurodegenerative Diseases Market

The global Targeted Drugs for Neurodegenerative Diseases market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The North American market for Targeted Drugs for Neurodegenerative Diseases is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for Targeted Drugs for Neurodegenerative Diseases is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for Targeted Drugs for Neurodegenerative Diseases in Parkinson's Disease (PD) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of Targeted Drugs for Neurodegenerative Diseases include Acadia Pharmaceuticals Inc., Kyowa Kirin, Supernus Pharmaceuticals, UCB, Sumitomo Pharma, Biogen, Eisai Inc., Eli Lilly, Green Valley, NOVARTIS, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global Targeted Drugs for Neurodegenerative Diseases market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Targeted Drugs for Neurodegenerative Diseases. The Targeted Drugs for Neurodegenerative Diseases market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Targeted Drugs for Neurodegenerative Diseases market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Targeted Drugs for Neurodegenerative Diseases manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Targeted Drugs for Neurodegenerative Diseases Market Report

Report Metric Details
Report Name Targeted Drugs for Neurodegenerative Diseases Market
Segment by Type
  • Injection
  • Oral
Segment by Application
  • Parkinson's Disease (PD)
  • Alzheimer's Disease (AD)
  • Huntington's Disease (HD)
  • Tardive Dyskinesia (TD)
  • Multiple Sclerosis (MS)
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Acadia Pharmaceuticals Inc., Kyowa Kirin, Supernus Pharmaceuticals, UCB, Sumitomo Pharma, Biogen, Eisai Inc., Eli Lilly, Green Valley, NOVARTIS, Bristol-Myers Squibb, Janssen, Sanofi, Roche, Neurocrine, Lundbeck, Teva
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for Targeted Drugs for Neurodegenerative Diseases companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Targeted Drugs for Neurodegenerative Diseases Market report?

Ans: The main players in the Targeted Drugs for Neurodegenerative Diseases Market are Acadia Pharmaceuticals Inc., Kyowa Kirin, Supernus Pharmaceuticals, UCB, Sumitomo Pharma, Biogen, Eisai Inc., Eli Lilly, Green Valley, NOVARTIS, Bristol-Myers Squibb, Janssen, Sanofi, Roche, Neurocrine, Lundbeck, Teva

What are the Application segmentation covered in the Targeted Drugs for Neurodegenerative Diseases Market report?

Ans: The Applications covered in the Targeted Drugs for Neurodegenerative Diseases Market report are Parkinson's Disease (PD), Alzheimer's Disease (AD), Huntington's Disease (HD), Tardive Dyskinesia (TD), Multiple Sclerosis (MS)

What are the Type segmentation covered in the Targeted Drugs for Neurodegenerative Diseases Market report?

Ans: The Types covered in the Targeted Drugs for Neurodegenerative Diseases Market report are Injection, Oral

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Injection
1.2.3 Oral
1.3 Market by Application
1.3.1 Global Targeted Drugs for Neurodegenerative Diseases Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Parkinson's Disease (PD)
1.3.3 Alzheimer's Disease (AD)
1.3.4 Huntington's Disease (HD)
1.3.5 Tardive Dyskinesia (TD)
1.3.6 Multiple Sclerosis (MS)
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Perspective (2021–2032)
2.2 Global Targeted Drugs for Neurodegenerative Diseases Growth Trends by Region
2.2.1 Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 Targeted Drugs for Neurodegenerative Diseases Historic Market Size by Region (2021–2026)
2.2.3 Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Region (2027–2032)
2.3 Targeted Drugs for Neurodegenerative Diseases Market Dynamics
2.3.1 Targeted Drugs for Neurodegenerative Diseases Industry Trends
2.3.2 Targeted Drugs for Neurodegenerative Diseases Market Drivers
2.3.3 Targeted Drugs for Neurodegenerative Diseases Market Challenges
2.3.4 Targeted Drugs for Neurodegenerative Diseases Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Targeted Drugs for Neurodegenerative Diseases Players by Revenue
3.1.1 Global Top Targeted Drugs for Neurodegenerative Diseases Players by Revenue (2021–2026)
3.1.2 Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Players (2021–2026)
3.2 Global Top Targeted Drugs for Neurodegenerative Diseases Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by Targeted Drugs for Neurodegenerative Diseases Revenue
3.4 Global Targeted Drugs for Neurodegenerative Diseases Market Concentration Ratio
3.4.1 Global Targeted Drugs for Neurodegenerative Diseases Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Neurodegenerative Diseases Revenue in 2025
3.5 Global Key Players of Targeted Drugs for Neurodegenerative Diseases Head Offices and Areas Served
3.6 Global Key Players of Targeted Drugs for Neurodegenerative Diseases, Products and Applications
3.7 Global Key Players of Targeted Drugs for Neurodegenerative Diseases, Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 Targeted Drugs for Neurodegenerative Diseases Breakdown Data by Type
4.1 Global Targeted Drugs for Neurodegenerative Diseases Historic Market Size by Type (2021–2026)
4.2 Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Type (2027–2032)
5 Targeted Drugs for Neurodegenerative Diseases Breakdown Data by Application
5.1 Global Targeted Drugs for Neurodegenerative Diseases Historic Market Size by Application (2021–2026)
5.2 Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America Targeted Drugs for Neurodegenerative Diseases Market Size (2021–2032)
6.2 North America Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021–2026)
6.4 North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Targeted Drugs for Neurodegenerative Diseases Market Size (2021–2032)
7.2 Europe Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021–2026)
7.4 Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size (2021–2032)
8.2 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2021–2026)
8.4 Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America Targeted Drugs for Neurodegenerative Diseases Market Size (2021–2032)
9.2 Latin America Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021–2026)
9.4 Latin America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size (2021–2032)
10.2 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2021–2026)
10.4 Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Acadia Pharmaceuticals Inc.
11.1.1 Acadia Pharmaceuticals Inc. Company Details
11.1.2 Acadia Pharmaceuticals Inc. Business Overview
11.1.3 Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Introduction
11.1.4 Acadia Pharmaceuticals Inc. Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.1.5 Acadia Pharmaceuticals Inc. Recent Development
11.2 Kyowa Kirin
11.2.1 Kyowa Kirin Company Details
11.2.2 Kyowa Kirin Business Overview
11.2.3 Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Introduction
11.2.4 Kyowa Kirin Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.2.5 Kyowa Kirin Recent Development
11.3 Supernus Pharmaceuticals
11.3.1 Supernus Pharmaceuticals Company Details
11.3.2 Supernus Pharmaceuticals Business Overview
11.3.3 Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Introduction
11.3.4 Supernus Pharmaceuticals Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.3.5 Supernus Pharmaceuticals Recent Development
11.4 UCB
11.4.1 UCB Company Details
11.4.2 UCB Business Overview
11.4.3 UCB Targeted Drugs for Neurodegenerative Diseases Introduction
11.4.4 UCB Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.4.5 UCB Recent Development
11.5 Sumitomo Pharma
11.5.1 Sumitomo Pharma Company Details
11.5.2 Sumitomo Pharma Business Overview
11.5.3 Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Introduction
11.5.4 Sumitomo Pharma Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.5.5 Sumitomo Pharma Recent Development
11.6 Biogen
11.6.1 Biogen Company Details
11.6.2 Biogen Business Overview
11.6.3 Biogen Targeted Drugs for Neurodegenerative Diseases Introduction
11.6.4 Biogen Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.6.5 Biogen Recent Development
11.7 Eisai Inc.
11.7.1 Eisai Inc. Company Details
11.7.2 Eisai Inc. Business Overview
11.7.3 Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Introduction
11.7.4 Eisai Inc. Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.7.5 Eisai Inc. Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Eli Lilly Business Overview
11.8.3 Eli Lilly Targeted Drugs for Neurodegenerative Diseases Introduction
11.8.4 Eli Lilly Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.8.5 Eli Lilly Recent Development
11.9 Green Valley
11.9.1 Green Valley Company Details
11.9.2 Green Valley Business Overview
11.9.3 Green Valley Targeted Drugs for Neurodegenerative Diseases Introduction
11.9.4 Green Valley Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.9.5 Green Valley Recent Development
11.10 NOVARTIS
11.10.1 NOVARTIS Company Details
11.10.2 NOVARTIS Business Overview
11.10.3 NOVARTIS Targeted Drugs for Neurodegenerative Diseases Introduction
11.10.4 NOVARTIS Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.10.5 NOVARTIS Recent Development
11.11 Bristol-Myers Squibb
11.11.1 Bristol-Myers Squibb Company Details
11.11.2 Bristol-Myers Squibb Business Overview
11.11.3 Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Introduction
11.11.4 Bristol-Myers Squibb Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.11.5 Bristol-Myers Squibb Recent Development
11.12 Janssen
11.12.1 Janssen Company Details
11.12.2 Janssen Business Overview
11.12.3 Janssen Targeted Drugs for Neurodegenerative Diseases Introduction
11.12.4 Janssen Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.12.5 Janssen Recent Development
11.13 Sanofi
11.13.1 Sanofi Company Details
11.13.2 Sanofi Business Overview
11.13.3 Sanofi Targeted Drugs for Neurodegenerative Diseases Introduction
11.13.4 Sanofi Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.13.5 Sanofi Recent Development
11.14 Roche
11.14.1 Roche Company Details
11.14.2 Roche Business Overview
11.14.3 Roche Targeted Drugs for Neurodegenerative Diseases Introduction
11.14.4 Roche Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.14.5 Roche Recent Development
11.15 Neurocrine
11.15.1 Neurocrine Company Details
11.15.2 Neurocrine Business Overview
11.15.3 Neurocrine Targeted Drugs for Neurodegenerative Diseases Introduction
11.15.4 Neurocrine Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.15.5 Neurocrine Recent Development
11.16 Lundbeck
11.16.1 Lundbeck Company Details
11.16.2 Lundbeck Business Overview
11.16.3 Lundbeck Targeted Drugs for Neurodegenerative Diseases Introduction
11.16.4 Lundbeck Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.16.5 Lundbeck Recent Development
11.17 Teva
11.17.1 Teva Company Details
11.17.2 Teva Business Overview
11.17.3 Teva Targeted Drugs for Neurodegenerative Diseases Introduction
11.17.4 Teva Revenue in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
11.17.5 Teva Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
ACADIA Pharmaceuticals Inc.
Kyowa Kirin
Supernus Pharmaceuticals
UCB
Sumitomo Pharma
Biogen
Eisai Co Ltd
Eli Lilly
Green Valley
Novartis
Bristol–Myers Squibb
Janssen
Sanofi
Roche
Neurocrine
Lundbeck
TEVA
List of Tables
 Table 1. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Injection
 Table 3. Key Players of Oral
 Table 4. Global Targeted Drugs for Neurodegenerative Diseases Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 5. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 6. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Region (US$ Million), 2021–2026
 Table 7. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2021–2026)
 Table 8. Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 9. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2027–2032)
 Table 10. Targeted Drugs for Neurodegenerative Diseases Market Trends
 Table 11. Targeted Drugs for Neurodegenerative Diseases Market Drivers
 Table 12. Targeted Drugs for Neurodegenerative Diseases Market Challenges
 Table 13. Targeted Drugs for Neurodegenerative Diseases Market Restraints
 Table 14. Global Targeted Drugs for Neurodegenerative Diseases Revenue by Players (US$ Million), 2021–2026
 Table 15. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Players (2021–2026)
 Table 16. Global Top Targeted Drugs for Neurodegenerative Diseases Players by Tier (Tier 1, Tier 2, and Tier 3), based on Targeted Drugs for Neurodegenerative Diseases Revenue, 2025
 Table 17. Ranking of Global Top Targeted Drugs for Neurodegenerative Diseases Companies by Revenue (US$ Million) in 2025
 Table 18. Global 5 Largest Players Market Share by Targeted Drugs for Neurodegenerative Diseases Revenue (CR5 and HHI), 2021–2026
 Table 19. Global Key Players of Targeted Drugs for Neurodegenerative Diseases, Headquarters and Area Served
 Table 20. Global Key Players of Targeted Drugs for Neurodegenerative Diseases, Products and Applications
 Table 21. Global Key Players of Targeted Drugs for Neurodegenerative Diseases, Date of General Availability (GA)
 Table 22. Mergers and Acquisitions, Expansion Plans
 Table 23. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Type (US$ Million), 2021–2026
 Table 24. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Type (2021–2026)
 Table 25. Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 26. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Type (2027–2032)
 Table 27. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application (US$ Million), 2021–2026
 Table 28. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2021–2026)
 Table 29. Global Targeted Drugs for Neurodegenerative Diseases Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 30. Global Targeted Drugs for Neurodegenerative Diseases Revenue Market Share by Application (2027–2032)
 Table 31. North America Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 32. North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (US$ Million), 2021–2026
 Table 33. North America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (US$ Million), 2027–2032
 Table 34. Europe Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 35. Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (US$ Million), 2021–2026
 Table 36. Europe Targeted Drugs for Neurodegenerative Diseases Market Size by Country (US$ Million), 2027–2032
 Table 37. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 38. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region (US$ Million), 2021–2026
 Table 39. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size by Region (US$ Million), 2027–2032
 Table 40. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 41. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (US$ Million), 2021–2026
 Table 42. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size by Country (US$ Million), 2027–2032
 Table 43. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 44. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (US$ Million), 2021–2026
 Table 45. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size by Country (US$ Million), 2027–2032
 Table 46. Acadia Pharmaceuticals Inc. Company Details
 Table 47. Acadia Pharmaceuticals Inc. Business Overview
 Table 48. Acadia Pharmaceuticals Inc. Targeted Drugs for Neurodegenerative Diseases Product
 Table 49. Acadia Pharmaceuticals Inc. Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 50. Acadia Pharmaceuticals Inc. Recent Development
 Table 51. Kyowa Kirin Company Details
 Table 52. Kyowa Kirin Business Overview
 Table 53. Kyowa Kirin Targeted Drugs for Neurodegenerative Diseases Product
 Table 54. Kyowa Kirin Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 55. Kyowa Kirin Recent Development
 Table 56. Supernus Pharmaceuticals Company Details
 Table 57. Supernus Pharmaceuticals Business Overview
 Table 58. Supernus Pharmaceuticals Targeted Drugs for Neurodegenerative Diseases Product
 Table 59. Supernus Pharmaceuticals Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 60. Supernus Pharmaceuticals Recent Development
 Table 61. UCB Company Details
 Table 62. UCB Business Overview
 Table 63. UCB Targeted Drugs for Neurodegenerative Diseases Product
 Table 64. UCB Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 65. UCB Recent Development
 Table 66. Sumitomo Pharma Company Details
 Table 67. Sumitomo Pharma Business Overview
 Table 68. Sumitomo Pharma Targeted Drugs for Neurodegenerative Diseases Product
 Table 69. Sumitomo Pharma Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 70. Sumitomo Pharma Recent Development
 Table 71. Biogen Company Details
 Table 72. Biogen Business Overview
 Table 73. Biogen Targeted Drugs for Neurodegenerative Diseases Product
 Table 74. Biogen Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 75. Biogen Recent Development
 Table 76. Eisai Inc. Company Details
 Table 77. Eisai Inc. Business Overview
 Table 78. Eisai Inc. Targeted Drugs for Neurodegenerative Diseases Product
 Table 79. Eisai Inc. Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 80. Eisai Inc. Recent Development
 Table 81. Eli Lilly Company Details
 Table 82. Eli Lilly Business Overview
 Table 83. Eli Lilly Targeted Drugs for Neurodegenerative Diseases Product
 Table 84. Eli Lilly Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 85. Eli Lilly Recent Development
 Table 86. Green Valley Company Details
 Table 87. Green Valley Business Overview
 Table 88. Green Valley Targeted Drugs for Neurodegenerative Diseases Product
 Table 89. Green Valley Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 90. Green Valley Recent Development
 Table 91. NOVARTIS Company Details
 Table 92. NOVARTIS Business Overview
 Table 93. NOVARTIS Targeted Drugs for Neurodegenerative Diseases Product
 Table 94. NOVARTIS Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 95. NOVARTIS Recent Development
 Table 96. Bristol-Myers Squibb Company Details
 Table 97. Bristol-Myers Squibb Business Overview
 Table 98. Bristol-Myers Squibb Targeted Drugs for Neurodegenerative Diseases Product
 Table 99. Bristol-Myers Squibb Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 100. Bristol-Myers Squibb Recent Development
 Table 101. Janssen Company Details
 Table 102. Janssen Business Overview
 Table 103. Janssen Targeted Drugs for Neurodegenerative Diseases Product
 Table 104. Janssen Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 105. Janssen Recent Development
 Table 106. Sanofi Company Details
 Table 107. Sanofi Business Overview
 Table 108. Sanofi Targeted Drugs for Neurodegenerative Diseases Product
 Table 109. Sanofi Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 110. Sanofi Recent Development
 Table 111. Roche Company Details
 Table 112. Roche Business Overview
 Table 113. Roche Targeted Drugs for Neurodegenerative Diseases Product
 Table 114. Roche Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 115. Roche Recent Development
 Table 116. Neurocrine Company Details
 Table 117. Neurocrine Business Overview
 Table 118. Neurocrine Targeted Drugs for Neurodegenerative Diseases Product
 Table 119. Neurocrine Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 120. Neurocrine Recent Development
 Table 121. Lundbeck Company Details
 Table 122. Lundbeck Business Overview
 Table 123. Lundbeck Targeted Drugs for Neurodegenerative Diseases Product
 Table 124. Lundbeck Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 125. Lundbeck Recent Development
 Table 126. Teva Company Details
 Table 127. Teva Business Overview
 Table 128. Teva Targeted Drugs for Neurodegenerative Diseases Product
 Table 129. Teva Revenue in Targeted Drugs for Neurodegenerative Diseases Business (US$ Million), 2021–2026
 Table 130. Teva Recent Development
 Table 131. Research Programs/Design for This Report
 Table 132. Key Data Information from Secondary Sources
 Table 133. Key Data Information from Primary Sources
 Table 134. Authors List of This Report


List of Figures
 Figure 1. Targeted Drugs for Neurodegenerative Diseases Picture
 Figure 2. Global Targeted Drugs for Neurodegenerative Diseases Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Type: 2025 vs 2032
 Figure 4. Injection Features
 Figure 5. Oral Features
 Figure 6. Global Targeted Drugs for Neurodegenerative Diseases Market Size by Application (US$ Million), 2021–2032
 Figure 7. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Application: 2025 vs 2032
 Figure 8. Parkinson's Disease (PD) Case Studies
 Figure 9. Alzheimer's Disease (AD) Case Studies
 Figure 10. Huntington's Disease (HD) Case Studies
 Figure 11. Tardive Dyskinesia (TD) Case Studies
 Figure 12. Multiple Sclerosis (MS) Case Studies
 Figure 13. Targeted Drugs for Neurodegenerative Diseases Report Years Considered
 Figure 14. Global Targeted Drugs for Neurodegenerative Diseases Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 15. Global Targeted Drugs for Neurodegenerative Diseases Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 16. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Region: 2025 vs 2032
 Figure 17. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Players in 2025
 Figure 18. Global Targeted Drugs for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 19. The Top 10 and 5 Players Market Share by Targeted Drugs for Neurodegenerative Diseases Revenue in 2025
 Figure 20. North America Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 21. North America Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021–2032)
 Figure 22. United States Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 23. Canada Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. Europe Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. Europe Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021–2032)
 Figure 26. Germany Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. France Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. U.K. Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Italy Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Russia Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 31. Ireland Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. Asia-Pacific Targeted Drugs for Neurodegenerative Diseases Market Share by Region (2021–2032)
 Figure 34. China Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. Japan Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. South Korea Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. Southeast Asia Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. India Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 39. Australia & New Zealand Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Latin America Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Latin America Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021–2032)
 Figure 42. Mexico Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 43. Brazil Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. Middle East & Africa Targeted Drugs for Neurodegenerative Diseases Market Share by Country (2021–2032)
 Figure 46. Israel Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 47. Saudi Arabia Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 48. UAE Targeted Drugs for Neurodegenerative Diseases Market Size YoY Growth (US$ Million), 2021–2032
 Figure 49. Acadia Pharmaceuticals Inc. Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 50. Kyowa Kirin Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 51. Supernus Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 52. UCB Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 53. Sumitomo Pharma Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 54. Biogen Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 55. Eisai Inc. Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 56. Eli Lilly Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 57. Green Valley Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 58. NOVARTIS Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 59. Bristol-Myers Squibb Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 60. Janssen Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 61. Sanofi Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 62. Roche Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 63. Neurocrine Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 64. Lundbeck Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 65. Teva Revenue Growth Rate in Targeted Drugs for Neurodegenerative Diseases Business (2021–2026)
 Figure 66. Bottom-up and Top-down Approaches for This Report
 Figure 67. Data Triangulation
 Figure 68. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SecuX Technology Inc

SIMILAR REPORTS

Global Targeted Drugs for Parkinson s Disease Market Research Report 2024
Global Targeted Drugs for Alzheimer s Disease Market Research Report 2024
Global Neurodegenerative Disorder Therapeutics Market Research Report 2024
Neurodegenerative Diseases Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Neurodegenerative Disease Treatment Market Research Report 2024
Global Targeted Drugs for Huntington s Disease Market Research Report 2024
Neurodegenerative Disease Treatment Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Neurodegenerative Diseases Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drugs for Multiple Sclerosis Market Research Report 2024
Global Neurodegenerative Disease Market Insights Forecast to 2030
Global Neuroregeneration Therapy Market Research Report 2024
Global Neurologic Disorder Treatment Drug Market Research Report 2024
Global Neurological Biomarkers for Alzheimer s and Parkinson s Diseases Market Research Report 2025
Global Targeted Delivery Drugs Market Research Report 2024
Global Targeted Protein Degradation Drug Market Research Report 2024
Central Nervous System Disease Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Retinal Degenerative Disease Treatment Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Parkinson Treatment Drug Market Research Report 2025
Global Cardiometabolic Disease Drug Market Research Report 2024
Global Alzheimer s Drugs Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions